Eyes Down For AstraZeneca plc Results

It’s first-half time for drugs giant AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

astrazenecaWe haven’t had any results from AstraZeneca (LSE: AZN) (NYSE: AZN.US) since the failed takeover bid to see how things are going, but there will be many eyes, including Pfizer‘s no doubt, focused on first-half figures when we get them on Thursday 31 July.

The City is still forecasting a 15% drop in earnings per share (EPS) for the full year to December, but AstraZeneca has given us tantalising hints that a return to profit growth might actually happen before 2016 as many observers expect.

No surprises

At year-end 2013, the company did say that “Core EPS for 2014 is expected to decline in the teens at CER“, and that fits in with predictions, but we also heard that it “expects revenues in 2017 will be broadly in line with 2013“. That would amount to a healthy reversal after 2013 ended with a 6% fall in revenue to $25.7bn and a 23% drop in core EPS.

Revenues are down largely due to recent loss of some patent protections and increased competition from generic drugs, so a renewed development pipeline is clearly the priority right now — as it has been since Pascal Soriot took over the top job.

Pipeline progress

And it appears to be bearing fruit, as the firm’s first-quarter update released in April told us of “significant progress made towards achieving scientific leadership in core therapeutic areas“.

The company says it is making impressively good progress with a large number of things with very strange names, including the start of Phase III trials for cancer drug Olaparib and arthritis treatment Brodalumab. And four other programmes are advancing to Phase III.

With revenue for the quarter actually up 3% at constant exchange rates, Mr Soriot said that “revenue growth reflects the increasing contribution from the five growth platforms that showed strong performance“.

Tricky valuation

Looking at AstraZeneca’s share price, it’s clearly still buoyed by the Pfizer effect. It soared and stayed close to the £50 level while a takeover was looking like a serious possibility, but since the attempt was called off the shares have not retreated to pre-bid levels. At £44.25 now, the price is still up 33% over 12 months and that puts the shares on a forward P/E of 17.5.

But long-term investors should be ignoring that and evaluating AstraZeneca on its own fundamental performance — and I’m optimistic about the forthcoming H1 update.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool has no position in any of the shares mentioned.

More on Investing Articles

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »